Immuron Ltd — Board/Management Information 2015

Jul 27, 2015

==> picture [194 x 55] intentionally omitted <==

Immuron Appoints Chief Operating & Scientific Officer

28 July 2015, Melbourne, Australia: Immuron is pleased to announce the appointment of Dr. Jerry Kanellos to serve as the Company’s new Chief Operating and Scientific Officer.

Dr Jerry Kanellos has over twenty years experience in the pharmaceutical and biotechnology industry, and has held leadership roles in business development, project management, intellectual property portfolio management, research and development and senior management, and holds a PhD in Medicine from the University of Melbourne.

Dr. Kanellos spent five years with TransBio Limited where as Chief Operating Officer, he was responsible for the strategic identification, development and maintenance of commercial partnerships globally, along with development, management and maintenance responsibility for the intellectual property portfolio, research & development and technology transfer.

Prior to this, Dr. Kanellos work for five years as a consultant to the biotech industry and has provided development and commercialisation strategies for various bodies including academic institutes, private and publicly listed companies and government departments. He has also been involved in the establishment and management of several startup biotechnology companies.

During his ten years tenure in research and development at CSL Limited, Dr. Kanellos gained considerable experience in the drug development process, formulation development through to pharmaceutical scale-up and cGMP manufacture successfully leading the Chemistry, Manufacturing and Controls (CMC) programs for the approval, manufacture and launch of several products.

Immuron Chairman Dr. Roger Aston commented that:

“Dr. Kanellos’ past experience in vaccine development, clinical trial management, and regulatory affairs will provide great support to our Manufacturing capability and will compliment the efforts of Immuron’s VP of Innovation Dan Peres in the NASH and ASH Clinical Trial programs further development of other pipeline hyperimmune opportunities.

The Board wish to welcome Dr. Kanellos to the Company and believes he will be a very valuable addition to the team.”

Contacts:

Dr Roger Aston Amanda Loh Non-Executive Chairman Buchan Consulting +61 (0) 402 762 204 +61 (0)3 9866 4722

Suite 1, 1233 High Street www.immuron.com Armadale, Victoria AUSTRALIA 3143 ABN: 80 063 114 045

Phone: + 61 (0)3 9824 5254 Facsimile: + 61 (0)3 9822 7735